Tyr48-Ile212 with Human IgG1 Fc Tag at N-Terminus
50-60kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Wu P, et al. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin Immunol. 2008
Lim SM, et al. CLEC4C p.K210del variant causes impaired cell surface transport in plasmacytoid dendritic cells of amyotrophic lateral sclerosis. Oncotarget. 2016
Robak E, Braun M, Robak T. Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment. Cancers (Basel). 2023
Wilson NR, et al. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma. 2022
5. Riboldi E, et al. Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. J Biol Chem. 2011
Dendritic Cell Lectin (DLEC), also known as BDCA-2, CD303, HECL, and alternatively designated as CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein belonging to the C-type lectin family. DLEC is selectively expressed in plasmacytoid dendritic cells (pDCs) and its expression is downregulated as these cells mature.
pDCs are integral to the innate immune response, particularly in the production of IFN-alpha/beta upon exposure to Toll-like receptor (TLR) 7 and TLR9 agonists, such as microbial CpG DNA. The ligation of DLEC on pDCs with specific antibodies has been shown to attenuate the CpG-stimulated production of interferons and to modulate the Th1 response. Monoclonal antibodies targeting CLEC4C have demonstrated efficacy in achieving disease control in patients with cutaneous lupus erythematosus.
The suppression of IFN-alpha production mediated by CLEC4C is regulated through the masking and unmasking of galactose moieties on the protein. This mechanism represents a novel potential strategy for modulating immune responses in various pathological conditions.
1μg (R: reducing condition).
The purity of BDCA-2/DLEC Fc Chimera Protein, Cynomolgus is greater than 95% as determined by SEC-HPLC.
Immobilized BDCA-2/DLEC Fc Chimera Protein, Cynomolgus (Cat. No. UA011105) at 2.0μg/mL (100μL/well) can bind Purified anti-human CD303 (BDCA-2) Antibody with EC50 of 19.31-24.94 ng/mL.
您现在的位置：